For the year ending 2025-12-31, CLRB has $14,978,321 in assets. $5,059,134 in debts. $13,196,033 in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 13,196,033 | |||
| Prepaid expenses and other current assets | 842,432 | |||
| Total current assets | 14,038,465 | |||
| Property, plant & equipment, net | 549,405 | |||
| Operating lease right-of-use asset | 360,671 | |||
| Other long-term assets | 29,780 | |||
| Total assets | 14,978,321 | |||
| Accounts payable and accrued liabilities | 4,423,548 | |||
| Warrant liability | 226,000 | |||
| Lease liability, current | 100,189 | |||
| Total current liabilities | 4,749,737 | |||
| Lease liability, net of current portion | 309,397 | |||
| Total liabilities | 5,059,134 | |||
| Series d convertible preferred stock, 111.11 shares authorized 111.11 shares issued and outstanding as of december 31, 2025 and 2024-Series DConvertible Preferred Stock | 1,382,023 | |||
| Series e-2 preferred stock, 1,225.00 shares authorized 35.60 and 35.60 shares issued and outstanding as of december 31, 2025 and 2024, respectively-Series E2Preferred Stock | 520,778 | |||
| Common stock, 0.00001 par value 170,000,000 shares authorized 4,240,129 and 1,535,996 shares issued and outstanding as of december 31, 2025 and 2024, respectively | 42 | |||
| Additional paid-in capital | 277,149,844 | |||
| Accumulated deficit | -269,133,500 | |||
| Total stockholders' equity | 8,537,164 | |||
| Total liabilities and stockholders' equity | 14,978,321 | |||
Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc. (CLRB)